← All Sponsors
SPONSOR

ImmunoVaccine Technologies, Inc. (IMV Inc.)

Total Trials
1
Recruiting
1
Phases
Phase 2
Conditions studied: Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-cell Lymphoma
NCT04920617 Phase 2
Recruiting

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed Diffuse Large B-cell Lymphoma
United States, Australia, Canada View Trial →